🔖
Bu Makaleye Atıf Yap
OKAN, A. İ., TAMAM, L. (2022). Agomelatinin İndüklediği Makülopapüler Döküntü: Bir Olgu Sunumu. Nöropsikiyatri Arşivi, Cilt: 50 - Sayı: 4, 379–380. https://ajindex.com/articles/584743
Dergiler / Nöropsikiyatri Arşivi / 2013 / Cilt: 50 - Sayı: 4
Agomelatinin İndüklediği Makülopapüler Döküntü: Bir Olgu Sunumu
- Sayfa
- 379–380
- Yayın Tarihi
- 2022-10-19
- DOI
- —
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗Kaynakça (4)
- European medicines agency (EMEA), Assessment report for valdoxan (Rapporteur: Skovlund E, Co-Rapporteur: Salmonson TP) Rouillon F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int Clin Psychopharmacol 2006; s. 2131-2135. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders. 4th ed Washington, DC: American Psychiatric Publishing; 2000.
- Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-245. Howland RH. Understanding and assessing adverse drug reactions. J Psychosoc Nurs Ment Health Serv 2011; 4913-4915.
- McKenna JK, Leiferman KM. Dermatologic drug reactions. Immunol Allergy Clin North Am 2004; 24:399-423.
- Fornaro M, Prestia D, Colicchio S and Perugi G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Current Neuropharmacol 2010; 8:287-304.